Taken together, these data indicated that the high expression of FBXW4 is a feature of higher-risk AML, which is more frequently seen in older AML adults and those with high-risk karyotypes, suggesting its clinical significance in predicting clinical outcomes in AML patients. Here, FBXW4 is linked to acute myeloid leukemia.